ERBB2 and breast carcinoma: The role of pSTAT3 as a negative regulator of immune cell-mediated antitumor responses and as an oncogenic driver led us to hypothesize that pSTAT3 expression might be a predictor of resistance to trastuzumab therapy in patients with HER2-positive breast cancer.